Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Antidementia agents reported by Eisai

Jan. 2, 1997

Novel anticonvulsant approved by FDA

Dec. 31, 1996

Japanese researchers describe analgesic tripeptides

Dec. 31, 1996

First phase II results for Innapharma's peptide antidepressant

Dec. 30, 1996

New agents for CNS disorders claimed by HHS

Dec. 30, 1996

Copaxone approved by FDA

Dec. 24, 1996

AACTG begins phase II memantine trial

Dec. 24, 1996

T Cell Sciences reports progress on TCAR program

Dec. 24, 1996

Otsuka describes new analgesics

Dec. 24, 1996

Neuroprotective polypeptide reported by Amgen

Dec. 24, 1996

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...